Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Demethylation Therapy to Prevent Relapse of High-Risk Pediatric AML After Allo-HSCT
ChiCTR2200066776Phase 3Not yet recruiting
- Sponsor
- Children's Hospital of Soochow University
- Start
- Dec 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of decitabine and azacitidine in acute myeloid leukemia (AML), sponsored by Children's Hospital of Soochow University. Primary endpoints: disease-free survival, complete remission rate and 1 more. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
decitabineazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2200066776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066776.